Alzheimer's Disease and Dementia
Featured Topics
Lead story
Other featured articles
-
Alzheimer’s-Preventing Drugs May Already Exist – We Just Can’t Test Them
Many people who use statins to fight heart disease seem to be on a slower track for developing Alzheimer's compared to the rest of the population. Yet multiple hurdles stand in the way for this sort of study.
Posted in -
Some Blood Pressure Medications May Reduce Risk of Alzheimer’s, But Not For All Populations
Certain antihypertensive medications may prevent the onset of the disease, but only among black and white women and white men.
Posted in -
Accelerating Alzheimer’s Disease Drug Innovations from the Research Pipeline to Patients
Goldman, Fillit, and Neumann outline policy options that would lead to more innovation.
-
The Value of Delaying Alzheimer’s Disease Onset
Models show that the number of patients will more than double in 40 years, and costs associated with their care will nearly quintuple.
Posted in
About this section
Even small delays in the onset of Alzheimer's disease and dementia could have significant impacts for the patient, their family and caregivers, and the healthcare system more broadly. The Schaeffer Center's microsimulation models demonstrate there may be preventive measures we can take now to shape the nation's future health.
OUR EXPERTS ON ALZHEIMER'S DISEASE AND DEMENTIA PREVENTION
Our Work In Alzheimer's Disease and Dementia
-
Longitudinal Analysis of Dementia Diagnosis and Specialty Care Among Racially Diverse Medicare Beneficiaries
The burden of Alzheimer’s disease and other dementias is rapidly growing. Researchers found vast majority of dementia patients don’t receive specialty diagnosis and care.
-
Vast Majority of Dementia Patients Don’t Receive Specialty Diagnosis and Care, Study Finds
Researchers found the use of dementia specialty care is particularly low for Hispanics and Asians.
-
Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer’s Treatment
A report on Canadian readiness to deal with new Alzheimer’s disease treatments co-authored by Jakub Hlávka found that average wait times could reach 28 months and that the most pressing issue is a lack of dementia specialists.
-
NIH Awards USC School of Pharmacy, Price School of Public Policy 5-Year Grant to Support Minority Aging Research in Schaeffer Center
The $2.7 million award funds scholars pursuing research in health disparities in aging with an emphasis on Alzheimer’s disease.
Categorized in -
The Association of Multiple Anti-Hypertensive Medication Classes with Alzheimer’s Disease Incidence Across Sex, Race, and Ethnicity
The researchers find hypertension management treatments that include RAS-acting ARBs may, in addition to lowering blood pressure, reduce AD risk, particularly for white and black women and white men.
-
Racial and Ethnic Differences in Trends in Dementia Prevalence and Risk Factors in the United States
The researchers find disparities in dementia prevalence declined between blacks and whites and increased between Hispanics and whites.